|
|
楼主 |
发表于 2024-5-9 10:18:51
|
显示全部楼层
* r X8 _8 k6 M5 S o# G
我看了下，入选今年ASCO的中肿研究，有4项是随机、3期临床试验，2项鼻咽癌+2项肺癌，这4项应该都能发很不错的文章，其余1-2期的应该也有子刊的水平' Z& k4 g* r, G' R. d' L: @3 k
: C+ s6 r$ {0 L+ J6 R- J, k7 lIvonescimab combined with chemotherapy in patients with EGFR-mutant non-squamous non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor treatment (HARMONi-A): A randomized, double-blind, multi-center, phase 3 trial." |. U% I3 j, y
Ivonescimab联合化疗治疗接受EGFR-TKI治疗进展的EGFR突变非鳞状NSCLC患者(HARMONi-A)：一项随机、双盲、多中心、III期试验
: B- ^9 x: q5 _, Q) N讲者：张力 中山大学肿瘤防治中心) v. ~3 n# ~1 \
' Z& @& p) @, U% `/ DAdjuvant icotinib of 12 months or 6 months versus observation following adjuvant chemotherapy for resected EGFR-mutated stage II–IIIA non-small-cell lung cancer (ICTAN, GASTO1002): A randomized phase 3 trial.
8 r7 H+ v: S( F* H可切除EGFR突变II-IIIA期NSCLC接受12个月或6个月的埃克替尼辅助治疗对比辅助化疗后观察：一项随机III期试验(ICTAN，GASTO1002)& \1 d% _) C K. e2 R( A
讲者：王思愚 中山大学肿瘤防治中心
7 ^# O# k9 _& t% x2 I" T" P! @5 w- b @* d' X
Tislelizumab versus placebo combined with induction chemotherapy followed by concurrent chemoradiotherapy and adjuvant tislelizumab or placebo for locoregionally advanced nasopharyngeal carcinoma: Interim analysis of a multicenter, randomized, placebo-controlled, double-blind, phase 3 trial.
1 T4 B0 C0 o! V3 w8 ^) u4 _$ e, ~, O替雷利珠单抗对比安慰剂联合诱导化疗序贯同步放化疗，继以替雷利珠单抗或安慰剂辅助治疗局部晚期鼻咽癌：一项多中心、随机、安慰剂对照、双盲、III期试验的期中分析' b# }$ Q9 E8 D9 w- ], f
讲者：陈秋燕 中山大学肿瘤防治中心' @3 [8 D! G* W
' [/ N' N' }: b6 m
Adjuvant PD-1 blockade with camrelizumab in high-risk locoregionally advanced nasopharyngeal carcinoma (DIPPER): A multicenter, open-label, phase 3, randomized controlled trial.# n1 u; J! `+ b# z
卡瑞利珠单抗辅助治疗高危局部晚期鼻咽癌(DIPPER)：一项多中心、开放标签、III期随机对照试验, ~) }. m6 L, @/ a
讲者：刘需 中山大学肿瘤防治中心
+ T7 l* F6 I( s' `5 h; L4 Z- ~1 j7 X: F$ f$ T8 `# L+ b8 n2 W
|
|
[复制链接]
发表于 2024-5-9 08:59:18
